... BASKING RIDGE N.J. Nov. 26 /- VioQuestPh...(Logo: A HREF http://www.newscom.com/cgi-bin/prnh/20070117/NYW085LOG...The Phase IIa trial will evaluate the clinical efficacy and biological... We have reached a significant milestone in the development of Lenocta...

BASKING RIDGE, N.J., Nov. 26 /PRNewswire-FirstCall/ -- VioQuest
Pharmaceuticals (OTC Bulletin Board: VQPH) today announced the initiation
of a Phase IIa study of Lenocta(TM) (sodium stibogluconate), a novel
protein tyrosine phosphatase inhibitor, in combination with interferon
alpha, an immune stimulant approved for the treatment of hepatitis C,
hepatitis B and a number of cancers. The open-label Phase IIa study is
designed to enroll at least 12 more patients.

The Phase IIa trial will evaluate the clinical efficacy and biological
effectiveness of Lenocta at the highest tolerable dose in combination with
interferon alpha in patients with advanced-stage solid tumors.

"We have reached a significant milestone in the development of Lenocta
as a potential cancer therapy with the initiation of this trial," said
Michael D. Becker, President and Chief Executive Officer of VioQuest
Pharmaceuticals. "We will continue to advance our portfolio of novel
compounds for various cancer indications into clinical development, the
goal of this drug development organization."

Razelle Kurzrock M.D., Professor of Medicine Chair, Department of
Investigational Cancer Therapeutics at The University of Texas M.D.
Anderson Cancer Center is the lead principal investigator for the study,
while Aung Naing M.D. of the same institution and Claire Verschraegen M.D.
of The University of New Mexico Cancer Center are participating
co-principal investigators.

Data from the recently concluded Phase I trial for Lenocta demonstrated
pharmacodynamic activity in some solid tumors as demonstrated by increases
in the activities of natural killer cells, CD8 and type II dendritic cells.

About Lenocta

Lenocta, a pentavalent antimonial originally used for the treatment of
the parasitic disease leishmaniasis, is an inhibitor of multiple protein
tyrosine phosphatases (PTPases), specifically the src homology PTPase
(SHP-1 & SHP-2) and PTP1B. Lenocta has also been demonstrated to augment
cytokine signaling and responses in hemopoietic cell lines, which can
enhance the body's immune system. Preclinical testing of Lenocta has
demonstrated anti-tumor activity against a wide spectrum of cancers.

About PTPases

The protein tyrosine phosphatase superfamily of enzymes functions in a
coordinated manner with protein tyrosine kinases to control signaling
pathways that underlie a broad spectrum of fundamental physiological
processes and represent a new class of therapeutic targets. The PTPases
SHP-1 and SHP-2 modulate progenitor cell development, cellular growth,
tissue inflammation, cellular chemotaxis, and directly control cell
survival involving oxidative stress pathways. SHP-1 and SHP-2 are
fundamental for the function of several growth factor and metabolic
pathways with far reaching implications for disease pathways and disorders
such as diabetes, neurodegeneration, and cancer.

About VioQuest Pharmaceuticals

VioQuest focuses on acquiring, developing, and commercializing targeted
late preclinical and early clinical stage therapies with unique mechanisms
of action primarily for oncology and infectious diseases. VioQuest has
three targeted drug candidates in clinical development: VQD-002 which
inhibits Akt, a member of the serine/threonine-specific protein kinase
family that is amplified, overexpressed, and/or activated in prostate,
breast, ovarian, colorectal, pancreatic, and hematologic cancers;
Lenocta(TM), an inhibitor of specific protein tyrosine phosphatases SHP-1,
SHP-2, and PTP1B that has demonstrated clinical and biological activity in
solid tumors; and Xyfid(TM), a topical therapy which is being developed for
the treatment and prevention of chemotherapy-induced Hand-Foot Syndrome
(HFS). VioQuest anticipates commencing Phase II trials for VQD-002, and
Xyfid in the first half of 2008. In addition, VioQuest and the U.S. Army
are planning to submit a New Drug Application (NDA) to the U. S. Food and
Drug Administration (FDA) in 2008 for Lenocta for the treatment of
leishmaniasis.

This press release contains forward-looking statements that involve
risks and uncertainties that could cause VioQuest's actual results and
experiences to differ materially from the anticipated results and
expectations expressed in these forward-looking statements. These
forward-looking statements concern the timing, progress and results of the
clinical development, regulatory processes, and potential clinical trial
initiations of Lenocta. These statements are often, but not always, made
through the use of words or phrases such as anticipates, expects, plans,
believes, intends, and similar words or phrases. These statements are based
on current expectations, forecasts and assumptions that are subject to
risks and uncertainties, which could cause actual outcomes and results to
differ materially from these statements. These statements are subject to
various risks and uncertainties and include the possibility that the
results of clinical trials will not support VioQuest's claims, the
possibility that VioQuest's development efforts relating to its product
candidates, including Lenocta(TM), will not be successful, the inability to
obtain regulatory approval of VioQuest's product candidates, VioQuest's
reliance on third-party researchers to develop its product candidates, its
lack of experience in developing and commercializing pharmaceutical
products, and the possibility that its licenses to develop and
commercialize its product candidates may be terminated. Additional risks
are described in VioQuest's Annual Report on Form 10-KSB for the year ended
December 31, 2006. VioQuest assumes no obligation and does not intend to
update these forward-looking statements, except as required by law.

(Date:12/9/2016)... LLC announced today that Steven E. Dawson has been appointed as chief ... Photo - http://photos.prnewswire.com/prnh/20161209/447552 ... Harmar ... Mr. Dawson,s executive career includes leadership roles managing and executing transformation, ... brings to the company deep operational and leadership expertise, a strong financial ...

(Date:12/9/2016)... Research and Markets has announced the addition of the ... ... travel vaccines market to grow at a CAGR of 6.83% during ... and the growth prospects of the global travel vaccines market for ... generated from the sales of various vaccines administered to actively immunize ...

(Date:12/8/2016)... 8, 2016 IRIDEX Corporation (NASDAQ: IRIX ... shares of common stock, $0.01 par value (the "Offering" with ... offering. The final terms of the Offering will depend on ... there can be no assurance as to whether or when ... use the net proceeds it will receive from this offering ...